Full history for every metric is available with a Kvantra account
Apogee Therapeutics, Inc. (APGE)
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | - | - | 0 | 0 | 0 | 0 | 0 |
| Operating profit | $m | -286 | -328 | |||||
| Net profit | $m | - | - | -40 | -84 | -182 | -256 | -294 |
| EPS reported | $ | -4.22 | -4.34 | |||||
| Operating cashflow per share | $ | -3.75 | -3.23 | |||||
| Capex per share | $ | 0.08 | 0.00 | |||||
| FCF per share | $ | -3.83 | -3.23 | |||||
| Free cash flow | $m | -233 | -244 | |||||
| Net debt | $m | -725 | -972 | |||||
| Book value equity | $m | 904 | 1,195 | |||||
| Book value per share | $ | 14.89 | 15.83 | |||||
| Number of shares | m | 60.69 | 75.44 | |||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 5.07 | 7.00 | |||||
| P/S LTM | x | 0.00 | 0.00 | |||||
| P/FCF LTM | x | -19.69 | -34.26 | |||||
| EV/EBITDA LTM | x | -17.54 | -25.35 | |||||
| EV/Sales LTM | x | 0.00 | 0.00 | |||||
| Earnings Yield LTM | % | -5.58% | -2.89% | |||||
| FCF Yield | % | -5.08% | -2.92% | |||||
| Quality | ||||||||
| ROE | % | -28.30% | -29.88% | |||||
| ROIC | % | -31.29% | -25.23% | |||||
| Operating margin | % | 0.00% | 0.00% | |||||
| Gross margin | % | 0.00% | 0.00% | |||||
| FCF/Sales | % | - | - | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | - | - | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | -26.29 | -35.70 | |||||
| Net Debt/EBITDA | x | 0.48 | 0.34 | |||||
| EBIT/Net interest | x | 0.00 | -207.66 | |||||
| Net debt/market cap | % | -15.82% | -11.63% | |||||
| Net debt/Equity | x | -0.80 | -0.81 | |||||
| Gross debt/equity | x | 0.01 | 0.01 | |||||
Company overview
Apogee Therapeutics, Inc. is a biotechnology firm, operating via its subsidiary, dedicated to advancing biologic treatments for conditions such as atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and a range of other inflammatory and immunological disorders. Its primary focus includes APG777, a subcutaneous (SQ) monoclonal antibody (mAb) engineered for an extended half-life to treat AD, and APG808, a similarly formulated SQ extended half-life mAb targeting COPD. Furthermore, its earlier-stage pipeline features APG990, another SQ extended half-life mAb designed for AD, and APG222, comprising extended half-life subcutaneous antibodies also aimed at AD. Established in 2022, the company maintains its headquarters in Waltham, Massachusetts.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Apogee Therapeutics, Inc. (APGE)
Apogee Therapeutics, Inc. is a biotechnology firm, operating via its subsidiary, dedicated to advancing biologic treatments for conditions such as atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and a range of other inflammatory and immunological disorders. Its primary focus includes APG777, a subcutaneous (SQ) monoclonal antibody (mAb) engineered for an extended half-life to treat AD, and APG808, a similarly formulated SQ extended half-life mAb targeting COPD. Furthermore, its earlier-stage pipeline features APG990, another SQ extended half-life mAb designed for AD, and APG222, comprising extended half-life subcutaneous antibodies also aimed at AD. Established in 2022, the company maintains its headquarters in Waltham, Massachusetts.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free